Jardiance (empagliflozin) / Eli Lilly, Lupin, Boehringer Ingelheim - LARVOL DELTA

The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus. (PubMed, Echocardiography) - "Empagliflozin therapy was associated with significant EAT thinning and favorable within-subject changes in selected diastolic indices and cardiometabolic markers in T2DM patients without established cardiovascular disease. The magnitude of EAT reduction was not significantly correlated with changes in conventional metabolic or inflammatory parameters; however, given the single-arm design and absence of a control group, causal and mechanistic inferences cannot be made, and these findings should be considered hypothesis-generating. Future controlled studies are warranted to confirm these observations and clarify underlying mechanisms."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications. (PubMed, J Clin Med) - "We examine how their proximal tubular mechanism differs from conventional therapies such as loop diuretics, vaptans, and salt supplementation, and evaluate evidence from recent randomised and crossover trials demonstrating improved serum sodium and enhanced water excretion with empagliflozin and dapagliflozin. SGLT2 inhibitors represent a physiologically rational and potentially safer alternative in selected patients with SIADH, particularly where fluid restriction is poorly tolerated or ineffective. Although further large-scale studies are required to define their optimal positioning within treatment algorithms, current evidence supports their potential role as an emerging therapeutic option in SIADH management."

Journal • Review

Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial. (PubMed, Nephrol Dial Transplant) - P2 | "The UACR-lowering response of finerenone and empagliflozin scaled linearly with age (10% per decade) and sex (~20% more among women). The benefit of combination therapy was independent of age and sex."

Journal • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis. (PubMed, Med Sci (Basel)) - "In older adults, SGLT2i maintain a favorable benefit-risk profile, with significant reductions in mortality and SAEs, though risks of genital infections and volume depletion require vigilance. The risk of genital infections exhibits a strong dose-response relationship and increases markedly in the oldest adults, while the mortality benefit appears to be most pronounced in those aged 75 years and older. This study provides actionable insights for personalized therapy in geriatric care."

Clinical • Journal • Retrospective data • Review • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

Urinary tract infections, risk factors and antimicrobial resistance patterns in heart failure patients on sodium-glucose transporter 2 inhibitors: Evidence from Jakaya Kikwete Cardiac Institute in Tanzania. (PubMed, PLoS One) - "UTIs are common among HF patients on SGLT2 inhibitors, with E. coli as the predominant pathogen and a concerning resistance to commonly used antibiotics. These findings underscore the need for routine urine culture and sensitivity testing to guide appropriate therapy and promote antimicrobial stewardship, particularly in resource-constrained settings."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Nephrology • Pneumonia

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=242 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=580 | Recruiting | Sponsor: Hoffmann-La Roche | N=242 ➔ 580 | Trial completion date: May 2026 ➔ May 2028 | Trial primary completion date: May 2026 ➔ May 2028

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=242 | Active, not recruiting | Sponsor: Hoffmann-La Roche | N=133 ➔ 242 | Trial completion date: May 2024 ➔ May 2026 | Trial primary completion date: May 2024 ➔ May 2026

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=280 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Aug 2021 ➔ Jun 2022 | Trial primary completion date: Aug 2021 ➔ Jun 2022

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=280 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Mar 2023 ➔ Sep 2023 | Trial primary completion date: Mar 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=280 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2023 ➔ May 2024 | Trial primary completion date: Sep 2023 ➔ May 2024

Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=280 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2022 ➔ May 2023 | Trial primary completion date: Jun 2022 ➔ May 2023

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=260 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1/2 trial • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=133 | Active, not recruiting | Sponsor: Hoffmann-La Roche | N=280 ➔ 133

Enrollment change • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=260 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2018 ➔ Mar 2018

Enrollment open • Trial initiation date • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • PD-L1

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=280 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: May 2023 ➔ Jan 2023 | Trial primary completion date: May 2023 ➔ Jan 2023

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. (PubMed, Diabetes Obes Metab) - P3 | "Sitagliptin/empagliflozin FDC doses achieved improvements in glycaemic control at 24 weeks, which was maintained through 52 weeks. These benefits were accompanied by a favourable safety profile, including a very low risk of hypoglycaemia."

Journal • P3 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) (clinicaltrialsregister.eu) - P1/2 | N=100 | Not yet recruiting | Sponsor: Universitair Medisch Centrum Groningen

New P1/2 trial • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

BEYOND DIABETES: WHEN NEPHROTIC SYNDROME IS NOT DIABETIC NEPHROPATHY IN A PATIENT WITH LONG STANDING TYPE TWO DIABETES MELLITUS (ISN-WCN 2026) - "Her medications included biphasic human insulin 20 units in the morning and 12 units at night, empagliflozin 10mg daily, vildagliptin/metformin 50/500 once daily, telmisartan 40 mg once daily, and atorvastatin 80 mg at night .Glycemic control was sub-optimal (HbA1c 7.8%) and fundoscopy revealed no evidence of diabetic or hypertensive retinopathy.She reported intermittent joint pains without arthritis or constitutional symptoms.On examination, she was hemodynamically stable with bilateral pedal edema...There was no evidence of diabetic nephropathy, confirming primary membranous nephropathy.The patient was initiated on the modified Ponticelli regimen, consisting of oral corticosteroids alternating with oral cyclophosphamide...A high index of suspicion, serologic workup, and renal biopsy helped uncover primary membranous nephropathy in a diabetic patient, allowing timely immunosuppressive therapy with promising early response. Clinicians should, therefore, maintain..."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Glomerulonephritis • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

EFFECTS OF SGLT- 2 INHIBITORS ON ENDOTHELIAL FUNCTION IN CKD: ROLE OF THE ENOS T(-786)C POLYMORPHISM (ISN-WCN 2026) - "Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as dapagliflozin and empagliflozin, provide cardiovascular and renal protection beyond their glucose-lowering effects, partly by improving endothelial function. Nevertheless, the findings should be interpreted cautiously. Larger, multicenter studies and mechanistic investigations are warranted to confirm these associations and to better understand how genetic background may influence the endothelial and cardiovascular effects of SGLT-2 inhibitors in patients with chronic kidney disease."

Cardiovascular • Chronic Kidney Disease • Nephrology • NOS3

EFFICACY AND SAFETY OF FINERENONE AND EMPAGLIFLOZIN IN PATIENTS WITH INITIAL DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE: A CONFIDENCE TRIAL PRESPECIFIED ANALYSIS (ISN-WCN 2026) - "is the principal investigator on grants to Washington University from Biomea, Diamyd, Breakthrough T1D (formerly Juvenile Diabetes Research Foundation), Lexicon, the National Institutes of Health, and Novo Nordisk; has received royalties or licenses from Washington University; has received consulting fees from Bayer, ClearNote Health, Lilly, Mannkind, Novo Nordisk, and Thermo Fisher; payment or honoraria from Medscape, Thermo Fisher, Bayer, Med Learning Group, and Baylor; has participated on a data safety monitoring board for the Jaeb Center, Washington University, and the National Institutes of Health; has received support for attending meetings and/or travel from the Endocrine Society, Mannkind, Western Endocrine Society, Kansas Diabetes Symposium; and holds a leadership or fiduciary role with the Diabetes Technology Access Group. R.A. has received nonfinancial support from Akebia Therapeutics, Alnylam, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Intercept,..."

Clinical • Late-breaking abstract • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • CLU • CST3 • KIM1 • LCN2 • SPP1

PHARMACOKINETICS, SAFETY AND EFFICACY OF EMPAGLIFLOZIN IN PAEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE: DESIGN OF THE EMPA-KIDNEY KIDS RANDOMISED CONTROLLED TRIAL (ISN-WCN 2026) - "BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. The study will be supported and funded by Boehringer Ingelheim.I did not use generative AI and AI-assisted technologies in the writing process."

Clinical • PK/PD data • Chronic Kidney Disease • Nephrology • Pediatrics • Renal Disease

TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IB WITH EMPAGLIFLOZIN AND ANGIOTENSIN II RECEPTOR BLOCKERS: A CASE SERIES (ISN-WCN 2026) - "Follow-up duration was 30 months.Results Following empagliflozin therapy, both patients demonstrated significant improvement in white blood cell (WBC) counts, allowing discontinuation of filgrastim in Patient 1 after WBC normalization and in Patient 2 one month after WBC normalization...Patient 2 continued stable microalbuminuria management with valsartan...The sustained 30-month benefit supports long-term efficacy. Further studies with larger cohorts are warranted to establish standardized treatment protocols and evaluate long-term renal and hematological outcomes in GSD-Ib patients treated with this dual therapeutic approach."

Clinical • Chronic Kidney Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hypoglycemia • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Neutropenia • Renal Disease

RENAL CYTOKINE PROFILE IMPROVEMENT WITH SGLT2 INHIBITORS IN ALBUMINURIC DIABETIC KIDNEY DISEASE (ISN-WCN 2026) - "At baseline, eGFR was 52 mL/min/1.73m2, median albuminuria was 838 mg/g (59.9% A3), BMI 30.1 kg/m2, and HbA1c 6.8%; 83% were on ACEi/ARB, 63.8% on metformin, 26.8% on GLP-1 RA, and 27.8% on insulin. Dapagliflozin was started in 68 patients and empagliflozin in 4...She has received travel and congress fees support from Astra-Zeneca, Esteve, NovoNordisk, Boehringer-Ingelheim Lilly, Astellas, Otsuka, Novartis, Bayer, Alexion, GSK, and Baxter. She has participated in advisory boards adn scientific lectures organized by Astra-Zeneca, Boehringer-Ingelheim Lilly, Otsuka, Esteve, Mundipharma, NovoNordisk, Astellas, Novartis, Bayer, Alexion, GSK, Roche, and Baxter.I did not use generative AI and AI-assisted technologies in the writing process."

Chronic Kidney Disease • Diabetic Nephropathy • Inflammation • Nephrology • Renal Disease • CCL8 • CSF2 • CXCL10 • CXCL11 • CXCL8 • CXCL9 • IFNG • IL10 • IL13 • IL15 • IL18 • IL1B • IL2 • IL4 • IL6 • IL7